New Approaches in Commercial Development of Artificial Oxygen Carriers

Simoni, Jane M.

doi:10.1111/aor.12371

Cited by 9 publications

(5 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, the interaction between synthetic microparticles and biological systems has also been an important area of research in the last several years; for example, the development of artificial oxygen carriers to substitute RBCs in the body [ 74 , 75 , 76 , 77 , 78 ], but it is beyond the main scope of the present review focused on blood particulate analogue fluids for in vitro studies.…”

Section: Rbc Templatesmentioning

confidence: 99%

Blood Particulate Analogue Fluids: A Review

et al. 2021

View full text Add to dashboard Cite

Microfluidics has proven to be an extraordinary working platform to mimic and study blood flow phenomena and the dynamics of components of the human microcirculatory system. However, the use of real blood increases the complexity to perform these kinds of in vitro blood experiments due to diverse problems such as coagulation, sample storage, and handling problems. For this reason, interest in the development of fluids with rheological properties similar to those of real blood has grown over the last years. The inclusion of microparticles in blood analogue fluids is essential to reproduce multiphase effects taking place in a microcirculatory system, such as the cell-free layer (CFL) and Fähraeus–Lindqvist effect. In this review, we summarize the progress made in the last twenty years. Size, shape, mechanical properties, and even biological functionalities of microparticles produced/used to mimic red blood cells (RBCs) are critically exposed and analyzed. The methods developed to fabricate these RBC templates are also shown. The dynamic flow/rheology of blood particulate analogue fluids proposed in the literature (with different particle concentrations, in most of the cases, relatively low) is shown and discussed in-depth. Although there have been many advances, the development of a reliable blood particulate analogue fluid, with around 45% by volume of microparticles, continues to be a big challenge.

show abstract

Section: Rbc Templatesmentioning

confidence: 99%

Blood Particulate Analogue Fluids: A Review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Nicht [24]. Deshalb hat sich die Strategie bei der Entwicklung von künstlichen Sauerstofftransportern in den letzten Jahren verändert und fokussiert auf Sauerstofftherapeutika [25,26] in Verbindung mit Drug Delivery [27].…”

Section: Introductionunclassified

Künstliche Sauerstofftransporter können mehr als Sauerstoff liefern

Bäumler

2020

Transfusionsmedizin - Immunhämatologie · Hämotherapie · Transpl

View full text Add to dashboard Cite

ZusammenfassungZum gegenwärtigen Zeitpunkt ist in der EU und den USA kein artifizieller Sauerstofftransporter zugelassen. Hämoglobin-basierte Sauerstoff-Carrier (HBOC) sind bereits seit Jahrzehnten Gegenstand wissenschaftlicher Untersuchungen. Ein wesentliches Hindernis bei der Zulassung war bisher der Anspruch der Entwickler, einen universell einsetzbaren Blutersatz zu produzieren. Die Beschränkung auf eine Indikation scheint erfolgversprechender zu sein. Der Ansatz, nicht nur Sauerstoff von der Lunge zum Gewebe, sondern auch der Abtransport von Kohlendioxid vom Gewebe zur Lunge zu transportieren, der effektiver als mit Erythrozyten durchgeführt werden kann, erscheint besonders attraktiv. Aufgrund vielversprechender präklinischer sowie klinischer Untersuchungen besteht die Hoffnung, dass in absehbarer Zeit auch in der EU künstliche Sauerstofftransporter für therapeutische Zwecke zur Verfügung stehen werden.

show abstract

“…At the moment the necessity of blood transfusions is growing while the willingness. To donate blood is declining [4][5][6]. Major requirements for an artificial oxygen carrier are of course the ability to transport both, oxygen and carbon dioxide, but also the possibility to be stored easily for a long time without any loss in quality.…”

Section: Introductionmentioning

confidence: 99%

Improved Albumin-Derived Per Fluorocarbon- Based Artificial Oxygen Carriers: In-vivo Evaluation of Biocompatibility

Ferenz¹

2017

AIBM

View full text Add to dashboard Cite

Despite long lasting efforts, an artificial oxygen carrier displaying adequate gas solubility combined with a minimal risk of side effects is missing at present for clinical use, both in Europe and USA. To bypass this bottleneck, recently developed albumin-derived per fluorocarbonbased nanocapsules were further improved and tested in-vivo. Most importantly, this second nanocapsule generation reached a smaller size distribution that resulted in partially less side effects compared to the first capsule formulation. The intravenous administration to healthy rats was tolerated without any noticeable abnormalities. Systemic and blood parameters stayed within the physiological range. Minor side-effects could be observed in the release of intracellular enzymes specific for organ damage. The intravascular half -life of the second generation of albumin-derived per fluorocarbon-based nanocapsules was ameliorated with regard to the first generation. Thus, the further improved albuminderived per fluorocarbon-based nanocapsules should be tested in much more advanced and clinical relevant models

show abstract

New Approaches in Commercial Development of Artificial Oxygen Carriers

Cited by 9 publications

References 19 publications

Blood Particulate Analogue Fluids: A Review

Blood Particulate Analogue Fluids: A Review

Künstliche Sauerstofftransporter können mehr als Sauerstoff liefern

Improved Albumin-Derived Per Fluorocarbon- Based Artificial Oxygen Carriers: In-vivo Evaluation of Biocompatibility

Contact Info

Product

Resources

About